Abstract
Sarcopenia, a degenerative skeletal muscle disease closely related to aging, has become a major threat to the health and quality of life of older adults. With the global trend of population aging, the social and economic problems caused by sarcopenia are becoming increasingly prominent. Currently, pharmacological treatments for sarcopenia are somewhat limited, whereas nutritional interventions have shown potential advantages in combating the condition. This review comprehensively discusses the bioactive components and functional properties of edible fungi and provides a thorough understanding of the severe health issues faced by sarcopenia patients, such as muscle degeneration and functional loss. Although animal experiments and early human studies support the positive effects of edible fungi, large-scale nutritional epidemiology studies in humans are still insufficient, which limits their application in the prevention and treatment of sarcopenia. Therefore, future research, such as randomized controlled trials, is needed to fully understand their effects on muscle health and to provide a solid scientific basis for the prevention and management of sarcopenia.
Introduction
Sarcopenia is a progressive skeletal muscle disease characterized by the loss of muscle mass and function, leading to increased risks of falls, fractures, and loss of independence in older adults. As the global population ages, the prevalence of sarcopenia—estimated between 5% and 22%—presents a mounting economic and social burden. Despite its impact, there are currently no approved pharmacological treatments specifically for sarcopenia. While physical exercise remains a cornerstone of management, dietary interventions represent a critical, modifiable factor that remains under-researched. This review explores whether the unique nutritional profile and bioactive components of edible fungi (mushrooms) can effectively slow or reverse muscle degeneration.
Methodology
This review synthesizes findings from 103 peer-referenced sources to evaluate the intersection of mycology and geriatric muscle health. The analysis covers:
- Diagnostic Frameworks: Comparing criteria from the European Working Group on Sarcopenia in Older People (EWGSOP) and the Asian Working Group for Sarcopenia (AWGS).
- Pathophysiological Drivers: Investigating molecular mechanisms of muscle loss, particularly the imbalance between protein synthesis and breakdown.
- Biochemical Profiling: Assessing the roles of fungal metabolites—including polysaccharides, dietary fibers, steroids, and polyphenols—in muscle repair and energy metabolism.
The review also draws upon significant population-level data, including the TCLSIH Cohort Study (n = 32,308) correlating mushroom consumption with handgrip strength, and clinical trial data involving species such as Hericium erinaceus (Lion's Mane) and Agaricus brasiliensis.
Key Insights: Mechanisms of Action
Edible fungi serve as "functional foods" that offer more than basic nutrition. Their bioactive compounds act as master regulators in muscle tissue:
1. Oxidative Stress and Mitochondrial Protection
Polysaccharides from species like Lentinula edodes (Shiitake) can directly scavenge reactive oxygen species (ROS). This protection is vital for maintaining mitochondrial DNA integrity, preventing the oxidative damage that typically triggers muscle atrophy.
2. Enhanced Muscle Perfusion and Respiration
Immunologically active substances in black wood ear (Auricularia auricula-judae) promote the release of nitric oxide (NO). As a vasodilator, NO improves blood flow to skeletal muscles, enhancing mitochondrial respiration and directly combating muscle fatigue.
3. Metabolic Signaling Pathways
Fungal extracts appear to activate key metabolic pathways, specifically AMPK and PPAR-δ. These pathways are essential for energy homeostasis; animal models have demonstrated that their activation significantly increases muscle endurance and reduces blood lactate levels post-exercise.
4. Mitigation of "Inflammaging"
Sarcopenia is often driven by chronic low-grade inflammation, or "inflammaging." Fungal compounds inhibit pro-inflammatory cytokines like IL-6, helping to restore the balance between muscle hypertrophy and atrophy.
Clinical and Epidemiological Evidence
The potential of fungi is supported by both observational and experimental data:
- Handgrip Strength: Large-scale studies (n > 32,000) show a positive correlation between frequent mushroom consumption and higher handgrip strength, a primary diagnostic marker for sarcopenia.
- Endurance and Recovery: In animal studies, mice supplemented with edible fungi for eight weeks showed significantly improved endurance and lower levels of fatigue biomarkers.
- Aging Biomarkers: Fungal extracts have been shown to inhibit the expression of lipofuscin and advanced glycation end products (AGEs), which are key indicators of cellular aging in muscle tissue.
Limitations and Future Directions
Despite compelling molecular and animal data, a "translational gap" remains. Current evidence is heavily weighted toward animal models and observational studies, leaving large-scale human nutritional epidemiology insufficient for clinical guidelines.
Future research must prioritize:
- Randomized Controlled Trials (RCTs): Establishing causation through gold-standard human trials.
- Species Specificity: Identifying which fungal species (e.g., Chaga vs. Shiitake) are most effective for specific sarcopenia phenotypes.
- Optimization: Determining the precise dosage and bioavailability of fungal polysaccharides required to elicit therapeutic effects in human muscle.
Conclusion
Edible fungi represent a promising, non-pharmacological strategy for preserving muscle health in aging populations. By leveraging their anti-inflammatory and antioxidant properties, mushrooms could become a staple in nutritional interventions against sarcopenia. However, rigorous clinical validation is essential before these functional foods can be formally integrated into treatment protocols.
Summary updated